|
Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment by using a genuine medical doctor. We aren't mDs. Always confer with your doctor on Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia Clinical research trials and Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia healthcare trials occur in a lot of of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new does drugs. The role of the studies / undertakings is to solve specific human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to find treatments for all kinds of conditions, including Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia. Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia Clinical Trials and other clinical trials allow for volunteers to access health treatment choices before they are available to the general public. Many times the test subjects get treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia clinical trial. Test subjects typically receive the most effective healthcare possible for their Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia condition. Risks are a reality, nonetheless, and could include extra or frequent dr. calls, health hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "R" Clinical Trials Conditions > Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia  Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia
Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia
For Condition: Aplastic Anemia
Status: Recruiting
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: This study will compare two new treatments for people with severe aplastic anemia, a potentially fatal disease in which patients do not produce normal numbers of blood cells. Because they have too few red cells, patients may tire easily, have chest pains, and be short of breath even at rest. Too few white cells leave patients vulnerable to serious infections and possibly death. Too few platelets cause abnormal bleeding and easy bruising. Bleeding in the brain (stroke) can be fatal. Standard treatment with horse antithymocyte globulin (h-ATG), cyclosporine (CsA), and corticosteroids is effective, but patients often relapse. The treatments to be evaluated in this study are: 1) rabbit ATG (r-ATG) plus CsA plus corticosteroids; and 2) Campath-1H. r-ATG is made by injecting rabbits with white blood cells. The rabbit's immune system makes antibodies to destroy the foreign white cells. The antibodies are collected and purified to make r-ATG. CsA is commonly used to prevent rejection of donated tissue after bone marrow or organ transplantation and, in combination with h-ATG, for treating aplastic anemia. Corticosteroids suppress the immune system and are given to prevent or reduce the symptoms of serum sickness, which can develop in response to the rabbit proteins in the r-ATG. Campath-1H is a laboratory-made antibody currently used to treat chronic lymphocytic leukemia. It destroys white blood cells called lymphocytes that, in aplastic anemia, are responsible for destruction of bone marrow stem cells. Patients 15 years of age and older with severe aplastic anemia may be eligible for this study. Candidates will be screened with a medical history, physical examination, blood tests, and bone marrow biopsy. Participants are randomly assigned to one of two treatment groups: 1) r-ATG, CsA, and steroids, or 2) Campath-1H. For both treatments, it is suggested that a central venous line (large plastic tube) be placed in a large vein in the neck or chest. This tube can stay in the body and be used the entire treatment period to deliver the study drug and other medications, transfuse blood, and withdraw blood samples. Group 1 patients receive r-ATG by vein for 5 days, CsA by mouth as a liquid or capsule for 6 months, and a full dose of steroids by mouth for at least 2 weeks. After 2 weeks, when the risk of serum sickness-a reaction to the r-ATG-declines, the steroid dose is decreased. Group 2 patients receive Campath-1H by vein for 10 days. Because this drug suppresses the immune system, patients also take medicines to prevent herpes virus infection and Pneumocystis carinii-a type of pneumonia-and to treat cytomegalovirus infection, if it develops. All patients are hospitalized for the initial testing and treatment (about 2 weeks) when the risk of infection and seizures is highest. In addition to drug treatment, patients undergo the following procedures: - Blood tests: Throughout the hospital admission, blood samples are drawn daily to check drug side effects and the response to treatment. Samples are drawn less frequently for later tests. - Bone marrow examination: A bone marrow sample is collected before beginning treatment, at 6 months, and then yearly. For this test, the area above the hip bone is numbed with a local anesthetic and a small sample of bone and marrow is withdrawn through a needle. - Chest x-ray may be done upon admission. - Other blood tests and x-rays may be required to evaluate and treat symptoms that may develop. - Follow-up: Blood tests are done weekly by the patient's private doctor, and patients return to NIH for examinations at 3-month intervals.
Details: Severe aplastic anemia, characterized by pancytopenia and a hypocellular bone marrow, is effectively treated by immunosuppressive therapy, usually a combination of antithymocyte globulin (ATG) and cyclosporine (CsA). Survival rates following this regimen are equivalent to those achieved with allogeneic stem cells transplantation. However, approximately 1/3 of patients will not show blood count improvement after ATG/CsA. General experience and small pilot studies have suggested that such patients may benefit from further immunosuppression. Furthermore, analysis of our own clinical data suggest that patients with poor blood count responses to a single course of ATG, even when transfusion-independence is achieved, have a markedly worse prognosis than patients with robust hematologic improvement. The management of such cases is uncertain. This study will enroll patients who are either refractory to h-ATG (continued severe pancytopenia) or who have only modest improvement in blood counts (weak hematologic responders) to receive a second round of immunosuppression, delivered either as rabbit ATG (Thymoglobulin, r-ATG) or a humanized monoclonal antibody to T-cells, alemtuzumab (Campath-1H® (Registered Trademark)). Primary endpoint will be response rate at 3 months defined as no longer meeting criteria for severe aplastic anemia. Relapse, robustness of hematopoietic recovery at 3 months, survival and clonal evolution to paroxysmal nocturnal hemoglobinuria (PNH), myelodysplasia and acute leukemia will be the secondary endpoints.
Eligibility:
Study Type: Interventional, Treatment, Safety/Efficacy
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: Severe aplastic anemia confirmed at NIH by: Bone marrow cellularity less than 30% (excluding lymphocytes) At least two of the following: Absolute neutrophil count less than 500/uL; Platelet count less than 20,000/ uL; Reticulocyte count less than 60,000/ uL. Severe aplastic anemia refractory to one course of h-ATG/CsA defined after 3 months from treatment with lless or equal to 16 months from receiving h-ATG. Suboptimal response to initial immunosuppression with ATG/CsA as defined by platelet and reticulocyte count less than 50,000 /uL at 3 months. Age greater than 15 EXCLUSION CRITERIA: Serum creatinine greater than 2.5 mg/dL. Underlying carcinoma (except local cervical, basal cell, squamous cell). Current pregnancy or lactation or unwillingness to take oral contraceptives. Diagnosis of Fanconi anemia or other congenital bone marrow failure syndromes. Evidence of a clonal disorder on cytogenetics. Previous hypersensitivity to Campath-1H or its components. Multiple courses of immunosuppression (greater than 2). Prior treatment with rabbit ATG, cyclophosphamide or a comparable agent. Underlying immunodeficiency state including seropositivity for HIV. Inability to understand the investigational nature of the study or give informed consent. Moribound status or concurrent hepatic, renal, cardiac, neurologic, pulmonary, infectious, or metabolic disease of such severity that it would preclude the patients ability to tolerate protocol therapy or that death within 7-10 days is likely. ECOG performance status greater than 2.
Total Enrollment: 120
Location and Contact Information:
National Heart, Lung and Blood Institute (NHLBI) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Patient and Public Liaison Office 1-800-411-1222
Additional Information:
Study ID Numbers: 030249; 03-H-0249
Study Start Date: July 16, 2003
Record last reviewed: July 7, 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00065260
Other Aplastic Anemia Studies:
1. Phase II Study of Bone Marrow Transplantation Using Related Donors in Patients with Aplastic Anemia
2. Megadose T-cell Depleted HLA-nonidentical Blood Progenitor Transplantation for Patients with Hematologic Malignancies or Bone Marrow Failure States
3. Stem Cell Mobilization Potential in Patients with Aplastic Anemia in remission
4. Collection of Biological Samples from Patients with Hepatitis-Associated Aplastic Anemia
5. Collection of Blood and Bone Marrow from Normal Volunteers and Patients for Research Purposes
Related Studies:
Other Aplastic Anemia Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia
|
|
|
|
|
|
|
|
